These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 30953957)
1. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. Lind J; Nordlund P Seizure; 2019 Jul; 69():20-24. PubMed ID: 30953957 [TBL] [Abstract][Full Text] [Related]
2. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort. Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060 [TBL] [Abstract][Full Text] [Related]
3. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301 [TBL] [Abstract][Full Text] [Related]
4. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. Smith KM; Britton JW; Hocker SE; Toledano M Neurologist; 2021 May; 26(3):80-82. PubMed ID: 33942787 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of rapid IV administration of valproic acid for status epilepticus. Rossetti AO; Bromfield EB Neurology; 2005 Aug; 65(3):500-1; author reply 500-1. PubMed ID: 16087935 [No Abstract] [Full Text] [Related]
6. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Hamed SA; Abdella MM Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Malamiri RA; Ghaempanah M; Khosroshahi N; Nikkhah A; Bavarian B; Ashrafi MR Eur J Paediatr Neurol; 2012 Sep; 16(5):536-41. PubMed ID: 22326977 [TBL] [Abstract][Full Text] [Related]
8. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821 [TBL] [Abstract][Full Text] [Related]
14. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Barrueto F; Hack JB Acad Emerg Med; 2001 Oct; 8(10):999-1001. PubMed ID: 11581089 [TBL] [Abstract][Full Text] [Related]
15. Intravenous sodium valproate in status epilepticus. Jha S; Jose M; Patel R Neurol India; 2003 Sep; 51(3):421-2. PubMed ID: 14652464 [TBL] [Abstract][Full Text] [Related]
16. Valproate-induced hyperammonemic encephalopathy: a case report and brief review of the literature. Sunkavalli KK; Iqbal FM; Singh B; Koneru J Am J Ther; 2013; 20(5):569-71. PubMed ID: 21248614 [TBL] [Abstract][Full Text] [Related]
19. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. Mink S; Muroi C; Seule M; Bjeljac M; Keller E Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756 [TBL] [Abstract][Full Text] [Related]
20. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M Medicine (Baltimore); 2017 Sep; 96(39):e8117. PubMed ID: 28953637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]